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Duchenne muscular dystrophy (DMD) (OMIM 
#310200) is an X-linked recessive inherited 
muscle-wasting disease characterised primarily by 
progressive weakness and atrophy of the skeletal 
and cardiac muscle. DMD patients are typically 
wheelchair-bound by 12 years of age and die in their late teens or 
early twenties of respiratory failure. It is one of the most common 
Mendelian disorders, occurring in all population groups with a 
birth prevalence of approximately 1/3 500 males. The disease gene, 
DMD, linked to chromosome Xp21.2, was one of the first genes 
to be isolated by positional cloning,[1] and the deficient product 
in affected boys was then identified as the protein dystrophin. [2] 
Dystrophin localises to the cell membrane in muscle cells and binds 
the protein actin, in this way forming part of the protein complex 
which links the cytoskeleton with the cell membrane. The gene is 
extremely large, spanning 2 400 kb of genomic DNA and comprising 
79 exons which encode a 14 kb transcript. Causative mutations are 
loss-of-function mutations:[3] approximately 65% are out-of-frame 
deletions of one or more complete exons; 5 - 10% are duplications; 
and the remainder are nonsense, splice site or frameshift mutations; 
missense mutations are rare. Complex rearrangements are seen in 
~2% of DMD cases. The new mutation rate is high, explained in 
part by the large size of the gene, and in approximately 1/3 of cases, 
the mother of an affected boy is not a carrier. Becker muscular 
dystrophy (BMD) (OMIM #300376) is a milder form of the disease, 
caused by mutations in the same gene. The effect of the mutations 
is different for BMD, and they lead to either a reduction in the 
amount, or an alteration in the size of the dystrophin protein, but 
not to a complete loss of protein as in DMD. [4] The mutation profile 
in BMD is different to DMD,[3] with ~85% of BMD mutations 
being accounted for by in-frame deletions, 5 - 10% by duplication 
mutations and the remainder by point mutations, splice site or small 
insertions/deletions.
The 5’ proximal end of dystrophin is more susceptible to duplication 
events and the most common exonic duplication mutation in DMD/
BMD patients has been shown to involve exon 2.[5] DMD and BMD 
are essentially clinically similar disorders, falling under the umbrella 
classification of ‘dystrophinopathies’, with DMD being the severe 
end of the spectrum and BMD a milder phenotype. The ‘reading 
frame rule’ may be applied to predict severity of disease in young 
children who represent simplex cases – if the mutation (deletion or 
duplication) results in an out-of-frame mutation, then this usually 
correlates with a more severe phenotype (DMD), and in-frame 
mutations generally correlate with the milder BMD phenotype.[4]
Two recombination hotspots for the large deletions have been 
identified: the proximal hotspot spans exons 2 - 7[6] and the distal 
hotspot spans exons 45 - 51.[7] Several multiplex polymerase chain 
reaction (mPCR) approaches have been developed to test for these 
deletions (testing approaches and PCR primer sequences can be 
found at the Leiden Open Variation Database (LOVD): http://www.
lovd.nl/dmd). These work on the principle that failure of an exon 
to amplify by PCR in hemizygous males indicates that the exon is 
deleted. PCR is a qualitative rather than a quantitative assay and is 
therefore insensitive to the copy number of the target sequence. Thus, 
duplication mutations in affected boys, and duplication or deletion 
mutations in heterozygous females cannot be identified using this 
technique. Consequently, carrier testing in at-risk females is not 
possible using the mPCR technique, and – prior to multiplex ligation-
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dependent probe amplification (MLPA) – was therefore carried out in 
the Molecular Diagnostic Laboratory, Division of Human Genetics, 
South African Institute for Medical Research (SAIMR) (now, the 
National Health Laboratory Service (NHLS)), University of the 
Witwatersrand, Johannesburg, by performing linked marker analysis. 
MLPA is a relatively simple, high-throughput and robust method 
developed by MRC-Holland.[8] The technique is based on the semi-
quantitative PCR principle and can be applied for detecting copy 
number changes. Using MLPA, the diagnosis of DMD/BMD-causing 
mutations has become more comprehensive as probes have been 
designed to detect deletions and duplications of all 79 exons of 
the dystrophin gene. This allows for accurate diagnostic, carrier 
and prenatal testing. MLPA can also identify smaller mutations if 
they occur within the probe-binding regions.[9] MLPA is currently 
the technique of choice as a first-line screen to detect deletions/
duplications in routine DMD/BMD genetic diagnostics.[10]
There are few published reports on DMD mutations in South 
African populations. Previous studies in this country have identified 
deletions in 50% (30/60) of affected boys, using the Southern blotting 
technique,[11] 42% (46/110) of affected boys using Southern blotting 
together with mPCR,[12] and 57% (39/68) of affected boys using the 
Chamberlain and Beggs mPCR approach.[13] All these studies included 
patients of different ethnic origins (black, Indian, mixed ancestry and 
white). Ballo et al.[12] reported a lower incidence of deletions in black 
patients (10/42; 26%) and suggested that other intragenic mutations, 
lying outside the two described hotspots, may be causative in this 
population group. However, Hallwirth Pillay et al.[13] did not find the 
same picture in their cohort of black patients, reporting a deletion 
detection rate similar to that in the literature (25/40; 62%).
Objectives
To (i) evaluate MLPA as a technique used for DMD/BMD diagnostic 
testing compared with the mPCR used previously in the laboratory; 
(ii) review the results of the testing performed in the laboratory 
to date; and (iii) assess and review the mutation profile in a larger 
cohort of DMD/BMD South African patients. The latter is important 
to characterise in light of new pharmacogenetic, or other therapeutic 
approaches which target specific mutations or gene regions.
Methods
Although a genetic counselling service for affected families has been 
available locally for four decades, a molecular diagnostic service for 
DMD/BMD was only established at the Division of Human Genetics, 
SAIMR and University of the Witwatersrand, in 2000. Prior to this, 
samples were referred for testing to the Department of Human 
Genetics at the University of Cape Town, where molecular testing 
techniques had been established and were available. 
Subjects
Patients were referred for DMD/BMD diagnostic testing from 
medical geneticists and genetic counsellors from the Clinical Section, 
Division of Human Genetics, and from doctors in public and private 
hospitals in the areas surrounding Johannesburg. Testing requests 
were also received from neighbouring provinces (Limpopo and 
KwaZulu-Natal). From January 2000 to May 2007, 128 unrelated 
probands were referred for such testing. These patients were 
investigated using an in-house mPCR method. During this time 
period, 45 carrier tests were undertaken in female family members, 
using linked marker analysis. Patients referred from May 2007 to 
April 2013 were tested using MLPA analysis. MLPA was performed 
on 261 probands and 57 at-risk female family members. In total, 
from April 2000 to April 2013, 11 prenatal tests have been carried 
out. Controls for all techniques were from unaffected, unrelated 
individuals available in the laboratory.
DNA extraction and quantification
For molecular analysis on probands and at-risk female family 
members requesting testing, blood was collected in EDTA tubes 
and DNA was extracted using either the salting-out protocol[14] or 
the High Preparation PCR Extraction kit (Roche Diagnostics) for 
samples where <1  ml of blood was received. DNA was quantified 
using a nanodrop spectrophotometer. Prenatal testing, following 
gender determination, was performed on uncultured samples 
obtained either by chorionic villus sampling or amniocentesis. DNA 
was extracted from prenatal samples using a phenol-chloroform 
protocol.[15]
mPCR assay and electrophoresis
mPCR was designed using the primer sequences for exons 4, 5, 8, 13, 17, 
19, 30, 42 - 45, 47, 49, 51, 60 and 62 described by Yau et al.[16] Primers for 
exons 1, 7, 9, 12 and 52 were obtained from the LOVD for DMD. Primers 
were fluorescently labelled. Each PCR run included a positive and a 
negative control sample. mPCR was performed using 100 - 200 ng of 
DNA. PCR products were loaded on the ABI377 Genetic Analyzer or on 
the ABI 3130xl Genetic Analyzer (Applied Biosystems). The presence/
absence of a PCR product was determined using GeneScan (ABI377) or 
GeneMapper version 4.0 (ABI 3130xl) software. 
MLPA analysis
MLPA analysis was performed using two SALSA MLPA kits specific 
for DMD/BMD testing (MRC-Holland). The SALSA P034 kit 
contains probes for exons 1 - 10, 21 - 30, 41 - 50 and 61 - 70 of 
the dystrophin gene while the SALSA P035 kit contains probes 
for the other exons in the dystrophin gene: exons 11 - 20, 31 - 40, 
51 - 60 and 71 - 79. Each MLPA run included four normal female 
control samples, one deletion-positive control sample and one 
duplication-positive control sample. MLPA was performed with 
5  μl of DNA (diluted in Tris-EDTA buffer to 40  ng/μl), according 
to the manufacturer’s instructions. PCR products were separated by 
electrophoresis on the ABI 3130xl Genetic Analyzer. The relative 
peak heights were extracted from the ABI 3130xl Genetic Analyzer 
using GeneMapper version 4.0 and analysed using an MS Excel-
based programme developed by the National Genetics Reference 
Laboratory, Manchester, UK (http://www.ngrl.org.uk/Manchester/
projects/informatics/mlpa). 
Sequencing analysis
Single exon deletions identified by MLPA were confirmed by 
standard PCR using primers from the mPCR (if the exon deleted was 
included in the mPCR multiplexes) or by ordering new primers with 
alternative primer binding sites. These PCR products were visualised 
on a 3% agarose gel (Whitehead Scientific). If the deleted exon did 
not amplify, this confirmed the deletion. If the deleted exon was 
present in the second assay, the exon was sequenced using automated 
Sanger sequencing.[17] Following sequencing, the samples were run 
with 10 μl Hi-Di formamide (Applied Biosystems) on the ABI 3130xl 
Genetic Analyzer. The results were analysed using Sequencing 
Analysis (Applied Biosystems) and Laser Gene, DNA Star software.
Linked marker analysis
Families where the proband tested negative for deletions using 
mPCR and negative for deletions/duplications using MLPA were 
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also offered linked marker analysis to identify the high-risk 
X chromosome. Carrier testing by linked marker analysis was 
performed using six intragenic, fluorescently labelled markers: 
5’DYS1, 5’DYS7, 5’DYS5, IVS44A, STR49 and DXS1214. Primer 
sequences for these linked markers were obtained from the LOVD 
website. Each PCR run included the affected proband in the 
family and a normal female and a normal male control sample. 
The six linked markers were divided into two multiplex reactions 
(IVS44A, 5’DYS5, DXS1214 and 5’DYS7, 5’DYS1, STR49). PCR 
products were loaded on the ABI377 Genetic Analyzer or on the 
ABI 3130xl Genetic Analyzer. The relative peak sizes were analysed 
using GeneScan (ABI377) or GeneMapper version 4.0 (ABI 3130xl) 
software to resolve dinucleotide repeat number.
Ethics consent for this study was obtained from the Ethics 
Committee of the University of the Witwatersrand (clearance 
certificate M110937).
Results
mPCR
Among the 128 probands tested using mPCR, 40 (31%) deletion 
mutations were identified (Table 1). 
MLPA 
Contiguous exon deletion or duplication results, as well as complex 
rearrangements were considered true findings and were not pursued 
further. Single exon deletion results on both MLPA and mPCR 
needed to be investigated to identify true single exon deletions and 
exclude the possibility of the presence of either a benign probe/
primer-binding mutation or a pathogenic probe/primer-binding 
mutation, both of which would give a false-positive ‘deletion’ 
mutation result.
Mutations were detected in 128/261 (49%) probands tested using 
MLPA (Table 2). The detection rate for each ethnic group was as 
follows: blacks 47.5%, Indians 53% and whites 42.5%.
Mutation profiles
The 128 mutations identified through MLPA analysis were separated 
into different categories for further consideration: 85 (66%) 
were contiguous exon deletions, 23 (18%) were contiguous exon 
duplications, five (4%) were true single exon deletions, seven (6%) 
were single exon duplications, four (3%) were complex rearrange-
ments and four (3%) were small mutations. The analysis of deletion 
or duplication mutations by position and ethnic background is 
provided in Table 3 and the complex rearrangements and small 
mutations are described in further detail below.
The majority of the contiguous exon deletion mutations (in all 
ethnic groups) were unique, except for a deletion of exon 3 - 7, which 
occurred in 4/63 black patients and in 3/17 of white patients (it was 
not determined if the breakpoints were similar). All contiguous 
duplication mutations were unique, except for a duplication of exons 
14 - 17, which occurred in 2/19 black patients. In black patients who 
carried a contiguous exon deletion mutation (n=63), the mutation 
was found in the 3’ distal region of the gene in 44 (70%) patients, 
showing that it is 2.3 times more likely for deletion mutations to 
occur in the distal region of the gene in this population group. The 
Table 1. The frequency of deletion mutations found in the 
DMD gene in South African DMD/BMD patients using 
mPCR
Ethnic group
Patients, 
n (%)
Patients with deletions, 
n (%)
Black 86 (67) 24 (28)
Indian 9 (7) 5 (56)
White 33 (26) 11 (33)
Total, N (%) 128 (100) 40 (31)
DMD = Duchenne muscular dystrophy; BMB = Becker muscular dystrophy;  
mPCR = multiplex polymerase chain reaction.
Table 2. The frequency of deletion/duplication mutations found in the DMD gene in South African DMD/BMD patients using 
MLPA analysis
Ethnic group Patients, n (%) Deletions, n (%) Duplications, n (%) Small indels or point mutations, n (%) Complex rearrangement, n (%)
Black 195 (75) 67 (34) 24 (12) 3 (1.1) 1 (0.4)
Indian 15 (6) 6 (40) 2 (13) 0 0
White 51 (19) 17 (33) 4 (8) 1 (0.4) 3 (1.1)
Total, N (%) 261 (100) 90 (34.5) 30 (11.5) 4 (1.5) 4 (1.5)
DMD = Duchenne muscular dystrophy; BMB = Becker muscular dystrophy; MLPA = multiplex ligation-dependent probe amplification; indels = insertions/deletions.
Table 3. Position of deletion or duplication mutations identified in the DMD gene, in the different South African ethnic groups 
studied
Ethnic group
Contiguous exon 
deletions, n (%)
Contiguous exon 
duplications, n (%)
Single exon deletions, 
n (%)
Single exon duplications, 
n (%)
Proximal* Distal† Proximal* Distal† Proximal* Distal† Proximal* Distal†
Black 19 (22) 44 (52) 13 (56) 6 (26) 1 (20) 3 (60) 5 (72) 1 (14)
Indian 3 (3.5) 2 (2.5) 1 (4.5) 1 (4.5) 0 1 (20) 0 0
White 8 (9.5) 9 (10.5) 1 (4.5) 1 (4.5) 0 0 1 (14) 0
Total, N (%) 85 (100) 23 (100) 5 (100) 7 (100)
*Exons 1 - 44.†Exons 45 - 79.
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clustering of deletion mutations in the 3’ deletion hotspot occurs 
globally,[3] so this result is in keeping with previously reported 
observations. The sample size of the Indian and white cohorts was 
small, and this possibly explains why this pattern was not observed 
in these ethnic groups. Contiguous and single exon duplication 
mutations were found more commonly in the 5’ proximal region 
of the gene (in all ethnic groups), this being in keeping with the 
international literature.[3]
MLPA single exon deletions
If the MLPA result was corroborated using PCR, a single exon deletion 
was confirmed in the patient. If PCR produced an amplification 
product, then the product was Sanger sequenced. Small mutations 
detected following sequencing are summarised in Table 4.
Complex rearrangements
Four probands were found to have unusual MLPA results. Three of 
these patients had non-contiguous exon duplications (an example is 
given in Fig. 1A) and one patient was found to have a contiguous exon 
deletion and a 7-fold non-contiguous exon duplication suggesting a 
complex rearrangement (Fig. 1B).
Prenatal testing
Before 2007 (prior to the availability of MLPA technology), fetal 
sexing was performed initially, followed by testing for the family 
mutation in a male fetus. From 2007 onwards, the presence of the 
family mutation could be tested using MLPA. Irrespective of time 
period, if the family mutation had not been identified, inheritance 
of the high-risk X chromosome from the mother was tracked in 
a male fetus using linked marker analysis. From 2000 to 2012, 11 
prenatal tests were undertaken. The family mutation was identified 
and screened for in 10/11 cases and one case was worked up using 
linked markers. The fetus was female in only one case (a reflection of 
the approach whereby ultrasound is used to sex the fetus and invasive 
prenatal testing is only performed on male fetuses or where fetal sex 
cannot be determined). In the 10 cases where the fetus was found 
to be male, a negative result for the familial pathogenic mutation 
was found in six cases, and four cases were positive for the familial 
mutation.
Alternate diagnoses
In cases where the clinical picture was unclear, testing requests for 
additional muscular dystrophies might have been requested by the 
referring clinician. These included requests for Charcot-Marie-Tooth 
type 1A, myotonic dystrophy and spinal muscular atrophy (SMA). 
A positive SMA result was found in five of the probands in this 
cohort. Further, in white patients, limb-girdle muscular dystrophy 
type 2I may present with a BMD/DMD phenotype (manuscript in 
preparation).
Discussion
In a multi-ethnic South African cohort of 390 DMD/BMD probands 
tested for DMD mutation status, it was found that MLPA has a 
higher detection rate than mPCR (49% v. 31%, respectively), which 
is consistent with the international literature. Considering that the 
overall detection rate for deletion mutations is similar for MLPA 
(34%) and mPCR (31%), it is clear that the advantage of MLPA lies 
mostly in the fact that it can detect duplication mutations (a further 
11.5% of mutations detected) and complex rearrangements (a further 
1.5% of mutations detected), and further deletions in regions not 
covered by mPCR. Small mutations that occur within MLPA probe-
binding sites were also found (another 1.5% of mutations detected). 
This is an unintended use of MLPA but presumably also occurs 
with mPCR. The mutation profile for the different ethnic groups 
studied here (black, Indian and white South African) is similar, with 
inconsistencies possibly being attributable to small sample size. This 
study does verify, however, that distal deletions in blacks are more 
common, and the distribution of deletion mutations in Indians and 
white South Africans should be confirmed on a larger cohort. The 
position of a deletion may be important because the exon-skipping 
gene therapy approach is aimed at distal mutations.
Since 33% of affected boys and 33% of mothers carry de novo 
mutations,[18] the lack of population-specific mutation profiles is 
not unexpected. Overall, deletion mutations were 3 - 4 times more 
common than duplications in all ethnic groups, and complex 
rearrangements and small mutations were rare.
While the reported detection rate for deletion mutations in the 
international literature is over 60%, in our laboratory lower detection 
rates have been found, irrespective of the molecular technique used 
for testing. It is suggested that this is a reflection of lack of rigour 
on the part of the clinicians referring a patient for DMD molecular 
testing, and not a reflection on the mutation profile of local DMD/
BMD patients. In certain patients, multiple genetic tests were 
requested, showing that DMD testing is sometimes being requested 
to exclude the diagnosis. Following from this study, it is apparent 
that more clearly defined clinical parameters need to be met before 
genetic testing is undertaken, including elevated serum creatine 
kinase levels. 
This study shows that using MLPA analysis for diagnostic, prenatal 
and carrier testing increases the sensitivity of identifying both 
deletion and duplication mutations in all 79 exons of the DMD gene. 
MLPA also detects complex rearrangements, although it does not 
define break points of duplicated material within the gene, which 
may be relevant for gene therapy. While sequencing analysis was 
used to confirm single exon deletions, ideally sequencing should also 
be used to confirm the extent of multi-exon deletion or duplication 
mutations.
It is very important to be aware of population-specific variants 
that occur within the MLPA probe-binding regions as these can 
Table 4. Small mutations detected in the DMD gene in male patients, by Sanger sequencing of the appropriate exon, previously 
shown to be ‘deleted’ using MLPA
Variant Exon Mutation, n (ethnicity) Pathogenicity
c.1554T→A/p.V505D 13 8 (black) Benign; MLPA probe-binding site variant
c.2012_2020duplCAGC 17 1 (black) Pathogenic; frameshift duplication
c.6801_6804delCAAA 47 2 (black) Pathogenic; frameshift deletion
c.8668C→T/p.R2870X 58 1 (white) Pathogenic; premature STOP codon
DMD = Duchenne muscular dystrophy; MLPA = multiplex ligation-dependent probe amplification.
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lead to false-positive results and misdiagnosis. When undertaking 
MLPA, it is imperative to establish an understanding of the local 
population variation. In the South African black population, a 
missense variant (c.1554T→A/p.V505D) was found in the probe-
binding region of exon 13. This variant is non-pathogenic, but gives 
a false-positive deletion result on MLPA analysis and occurs at a 
significant frequency.
MLPA is a direct and accurate method of testing that is now 
offered to at-risk females for carrier testing. The technique was used 
to establish the carrier status in 57 female relatives, negating the need 
for a lengthy and expensive linked-marker family work-up. MLPA 
is especially useful in sporadic/new mutation cases, where linked 
markers could refine risk but are not definitive, which mutation 
testing is. As MLPA is a direct mutation detection approach, it is 
also useful in prenatal testing cases where mothers may be germline 
mosaics.
Conclusion
The need to identify the pathogenic mutation in individuals affected 
by DMD is more apparent than ever, as significant progress is being 
Fig. 1. Complex rearrangements of the DMD gene in male patients, as detected by MLPA. (A) A non-contiguous duplication (exons 5 - 8 and 22 - 30); (B) a 
deletion (exons 22 - 25) and a 7-fold non-contiguous duplication (exons 53 - 70, 72 - 77 and 79).
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made on the therapeutic front. The most promising therapeutic 
approaches are nonsense mutation read-through and antisense 
oligonucleotide-induced exon skipping.[19] While nonsense mutations 
cause about 10% of DMD, theoretically over 80% of patients could be 
treated with antisense oligonucleotides. By this approach, the cellular 
machinery can be ‘fooled’ into bypassing an exon containing a point 
mutation/deletion/duplication such that the dystrophin protein is 
still produced, even though it will be in an altered form – with the 
net clinical effect of converting DMD to a BMD phenotype. Early 
diagnosis, identification of the mutation and intervention will be key 
to any therapeutic approach. The finding that deletion mutations 
do cluster in the 3’ distal region of the gene in black patients is of 
significance when considering therapeutic approaches. 
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